A multivalent approach to drug discovery for novel antibiotics

Journal of Antibiotics

Volumn 61, Issue 10, 2008, Pages 595-602

  Long, Daniel D ^a   Aggen, James B ^a,b   Christensen, Burton G ^a   Judice, J Kevin ^a,b   Hegde, Sharath S ^a   Kaniga, Koné ^a,c   Krause, Kevin M ^a   Linsell, Martin S ^a,b   Moran, Edmund J ^a   Pace, John L ^a,d  

^a THERAVANCE INC   (United States)

^b Achaogen Inc   (United States)

^c M4 2A   (United States)

^d StratoPharm LLC   (United States)

Author keywords

lactam; Antibiotic; Bifunctional; Glycopeptide; MRSA; Multivalency; Multivalent

Indexed keywords

CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE BETA LACTAM HETERODIMER; LINEZOLID; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CELL WALL; DRUG DESIGN; DRUG DISCOVERY; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA;

EID: 57849119803     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2008.79     Document Type: Article

References (21)

1. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 39 Suppl A: 1-6 (1997); Neu HC. The crisis in antibiotic resistance. Science 257: 1064-1073 (1992)
2. Chavez-Bueno S, Bozdogan B, Katz K, Bowlware KL, Cushion N, Cavuoti D, Ahmad N, McCracken GH Jr, Appelbaum PC. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 49: 2283-2288 (2005)
3. Bush K. The impact of β-lactamases on the development of novel antimicrobial agents. Curr Opin Invest Drugs 3: 1284-1290 (2002); Berger-Bächi B, Rohrer S. Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 178: 165-171 (2002); Walsh CT, Fisher SL, Park I-S, Prahalad M, Zhu W. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem Biol 3: 21-28 (1996); Popieniek PH, Pratt RF. A fluorescent ligand for binding studies with glycopeptide antibiotics of the vancomycin class. Anal Biochem 165: 108-113 (1987)
4. Printsevskaya SS, Pavlov AY, Olsufyeva EN, Mirchink EP, Isakova EB, Reznikova MI, Goldman RC, Branstrom AA, Baizman ER, Longley CB, Sztaricskai F, Batta G, Preobrazhenskaya MN. Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl- D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria. J Med Chem 45: 1340-1347 (2002); Cooper RDG, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot 49: 575-581 (1996); Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Stratford RE, Cooper RDG. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other Gram-positive bacteria. Antimicrob Agents Chemother 39: 2585-2587 (1995); Nagarajan R. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot 46: 1181-1195 (1993)
5. Leadbetter MR, Adams SM, Bazzini B, Fatheree PR, Karr DE, Krause KM, Lam BT, Linsell MS, Nodwell MB, Pace JL, Quast K, Shaw J-P, Soriano E, Trapp SG, Villena JD, Wu TX, Christensen BG, Judice JK. Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424). J Antibiot 57: 326-336 (2004); Higgins DL, Chang R, Debabov D, Leung J, Wu T, Krause KM, Sandvik E, Hubbard J, Kaniga K, Schmidt Jr DE, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49: 1127-1134 (2005)
6. Glinka TW. Novel cephalosporins for the treatment of MRSA infections. Curr Opin Invest Drugs 3: 206-217 (2002)
7. Bush K, Macielag M, Clancy J. "Superbugs". New antibacterials in the pipeline. Emerging Drugs 5: 347-365 (2000)
8. Choi S-K. Synthetic Multivalent Molecules, Wiley & Sons, ISBN 0471563471 (2004)
9. Mammen M, Choi S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37: 2754-2794 (1998)
10. Wright D, Usher L. Multivalent binding in the design of bioactive compounds. Curr Org Chem 5: 1107-1131 (2001)
11. Griffin JH, Linsell MS, Nodwell MB, Chen Q, Pace JL, Quast KL, Krause KM, Farington L, Wu TX, Higgins DL, Jenkins TE, Christensen BG, Judice JK. Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. J Am Chem Soc. 125: 6517-6531 (2003); Nicolaou KC, Hughes R, Cho SY, Winssinger N, Labischinski H, Endermann R. 2001 Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis. Chem Eur J 7: 3824-3843 (2001); Nicolaou KC, Hughes R, Cho SY, Winssinger N, Smethurst C, Labischinski H, Endermann R. 2000 Target-accelerated combinatorial synthesis and discovery of highly potent antibiotics effective against vancomycin-resistant bacteria. Angew Chem Int Ed 39: 3823-3828 (2000); Adamczyk M, Moore JA, Rege SD, Yu Z. Investigations into self-association of vancomycin covalent dimers using surface plasmon resonance technology. Bioorg Med Chem Lett 9: 2437-2440 (1999); Rao J, Yan L, Lahiri J, Whitesides GM, Weis RM, Warren HS. Binding of a dimeric derivative of vancomycin to 1-Lys-d-Ala-d-lactate in solution and at a surface. Chem Biol 6: 353-359 (1999); Rao J, Yan L, Xu B, Whitesides GM. Using surface plasmon resonance to study the binding of vancomycin and its dimer to self-assembled monolayers presenting D-Ala-D-Ala. J Am Chem Soc 121: 2629-2630 (1999); Rao J, Whitesides GM. Tight Binding of a dimeric derivative of vancomycin with dimeric L-Lys-D-Ala-D-Ala. J Am Chem Soc 119: 10286-10290 (1997); Sundram UN, Griffin JH, Nicas TI. Novel vancomycin dimers with activity against vancomycin-resistant enterococci. J Am Chem Soc 118: 13107-13108 (1996)
12. Rodrigues PCA, Scheuermann K, Stockmar C, Maier G, Fiebig HH, Unger C, Mulhaupt R, Kratz F. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Biorg Med Chem Let 13: 355-360 (2003)
13. Portoghese PS. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem 44: 2259-2269 (2001)
14. Steinfeld T, Mammen M, Smith JAM, Wilson RD, Jasper JR. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharm 72: 291-302 (2007)
15. Morphy R, Rankovic Z. Designed multiple ligands. J Med Chem 48: 6523-6543 (2005)
16. Chemistry and Biology of β-Lactam Antibiotics, Vol. 11, Ed., Morin RB, Gorman M, pp 372-436, Academic Press, New York (1982)
17. Bryskier A. Cephems: fifty years of continuous research. J Antibiot 53: 1028-1037 (2000)
18. Malabarba A, Nicas TI, Thompson RC. Structural modifications of glycopeptide antibiotics. Med Res Rev 17: 69-137 (1997)
19. Judice JK, Fatheree PR, Lam BMT, Leadbetter MR, Linsell MS, Trapp SG, Yang G, Zhu Y. Preparation of glycopeptide derivatives as antibacterial agents. U.S., 6,392,012 (2002); Cooper RDG, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot 49: 575-578 (1996); Roberts GD, Carr SA, Rotterschaeffer S, Jeffs PW. Structural characterization of glycopeptide antibiotics related to vancomycin by fast atom bombardment mass spectrometry. J Antibiot 38: 713-720 (1985)
20. Rochon-Edouard S, Pestel-Caron M, Lemeland J-F, Caron F. In vitro synergistic effects of double and triple combinations of β-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 44: 3055-3060 (2000)
21. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved guideline, 5th ed., M7-A5. The Committee, Wayne, Penn. (2000)